{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T11:06:58Z","timestamp":1779188818110,"version":"3.51.4"},"reference-count":86,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology Letters"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.imlet.2017.12.001","type":"journal-article","created":{"date-parts":[[2017,12,13]],"date-time":"2017-12-13T08:38:10Z","timestamp":1513154290000},"page":"68-75","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Chemokines in systemic sclerosis"],"prefix":"10.1016","volume":"195","author":[{"given":"Jamie","family":"King","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Stratton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.imlet.2017.12.001_bib0005","doi-asserted-by":"crossref","first-page":"15002","DOI":"10.1038\/nrdp.2015.2","article-title":"Systemic sclerosis","volume":"1","author":"Allanore","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.imlet.2017.12.001_bib0010","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ajhg.2013.12.002","article-title":"Immunochip analysis identifies multiple susceptibility loci for systemic sclerosis","volume":"94","author":"Mayes","year":"2014","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.imlet.2017.12.001_bib0015","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/art.1780200410","article-title":"Cellular infiltrates in scleroderma skin","volume":"20","author":"Fleischmajer","year":"1977","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.imlet.2017.12.001_bib0020","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/art.1780270607","article-title":"Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations","volume":"27","author":"Roumm","year":"1984","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.imlet.2017.12.001_bib0025","doi-asserted-by":"crossref","first-page":"182","DOI":"10.7326\/0003-4819-102-2-182","article-title":"Increased dermal mast cell populations in progressive systemic sclerosis: a link in chronic fibrosis?","volume":"102","author":"Hawkins","year":"1985","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.imlet.2017.12.001_bib0030","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40169-015-0047-4","article-title":"The significance of macrophage polarization subtypes for animal models of tissue fibrosis and human fibrotic diseases","volume":"4","author":"Wermuth","year":"2015","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.imlet.2017.12.001_bib0035","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1093\/rheumatology\/kes090","article-title":"T cells in systemic sclerosis: a reappraisal","volume":"51","author":"O'Reilly","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.imlet.2017.12.001_bib0040","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1097\/01.bor.0000139310.77347.9c","article-title":"Cellular origins of fibroblasts: possible implications for organ fibrosis in systemic sclerosis","volume":"16","author":"Postlethwaite","year":"2004","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.imlet.2017.12.001_bib0045","doi-asserted-by":"crossref","first-page":"e0134092","DOI":"10.1371\/journal.pone.0134092","article-title":"Partially evoked epithelial-mesenchymal transition (EMT) is associated with increased TGFbeta signaling within lesional scleroderma skin","volume":"10","author":"Nikitorowicz-Buniak","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.imlet.2017.12.001_bib0050","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1016\/j.ajpath.2015.03.019","article-title":"Endothelial to mesenchymal transition contributes to endothelial dysfunction in pulmonary arterial hypertension","volume":"185","author":"Good","year":"2015","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.imlet.2017.12.001_bib0055","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/labinvest.2010.73","article-title":"Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype","volume":"90","author":"Mathai","year":"2010","journal-title":"Lab. Invest."},{"key":"10.1016\/j.imlet.2017.12.001_bib0060","doi-asserted-by":"crossref","first-page":"e0126015","DOI":"10.1371\/journal.pone.0126015","article-title":"A role of myocardin related transcription factor-A (MRTF-A) in scleroderma related fibrosis","volume":"10","author":"Shiwen","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.imlet.2017.12.001_bib0065","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1093\/rheumatology\/keu155","article-title":"Epigenetics, the holy grail in the pathogenesis of systemic sclerosis","volume":"54","author":"Altorok","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.imlet.2017.12.001_bib0070","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13075-016-0929-x","article-title":"MicroRNAs in fibrosis: opportunities and challenges","volume":"18","author":"O'Reilly","year":"2016","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.imlet.2017.12.001_bib0075","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","article-title":"Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial","volume":"387","author":"Khanna","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.imlet.2017.12.001_bib0080","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/nrrheum.2014.137","article-title":"Transforming growth factor beta\u2013at the centre of systemic sclerosis","volume":"10","author":"Lafyatis","year":"2014","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.imlet.2017.12.001_bib0085","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.imlet.2017.12.001_bib0090","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1093\/rheumatology\/kev117","article-title":"Haematopoietic stem cell transplantation for poor-prognosis systemic sclerosis","volume":"54","author":"van Laar","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.imlet.2017.12.001_bib0095","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.cytogfr.2017.06.009","article-title":"Improving homing in T cell therapy","volume":"36","author":"Vignali","year":"2017","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.imlet.2017.12.001_bib0100","first-page":"95","article-title":"Chemokines and chemokine receptors: their manifold roles in homeostasis and disease","volume":"1","author":"Le","year":"2004","journal-title":"Cell Mol. Immunol."},{"key":"10.1016\/j.imlet.2017.12.001_bib0105","doi-asserted-by":"crossref","first-page":"4735","DOI":"10.1021\/acs.jmedchem.6b01309","article-title":"Structural analysis of chemokine receptor-ligand interactions","volume":"60","author":"Arimont","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.imlet.2017.12.001_bib0110","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.coph.2016.07.006","article-title":"Chemokines and their receptors: insights from molecular modeling and crystallography","volume":"30","author":"Kufareva","year":"2016","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.imlet.2017.12.001_bib0115","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1083\/jcb.92.2.584","article-title":"Platelet-derived growth factor in chemotactic for fibroblasts","volume":"92","author":"Seppa","year":"1982","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.imlet.2017.12.001_bib0120","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S0923-1811(00)00164-X","article-title":"Role of stem cell factor and monocyte chemoattractant protein-1 in the interaction between fibroblasts and mast cells in fibrosis","volume":"26","author":"Yamamoto","year":"2001","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.imlet.2017.12.001_bib0125","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/BF03403533","article-title":"Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair","volume":"1","author":"Bucala","year":"1994","journal-title":"Mol. Med."},{"key":"10.1016\/j.imlet.2017.12.001_bib0130","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1755-1536-4-15","article-title":"Altered monocyte and fibrocyte phenotype and function in scleroderma interstitial lung disease: reversal by caveolin-1 scaffolding domain peptide","volume":"4","author":"Tourkina","year":"2011","journal-title":"Fibrogenesis Tissue Repair"},{"key":"10.1016\/j.imlet.2017.12.001_bib0135","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1093\/rheumatology\/33.12.1131","article-title":"Familial scleroderma\u2013evidence for environmental versus genetic trigger","volume":"33","author":"Stephens","year":"1994","journal-title":"Br. J. Rheumatol."},{"key":"10.1016\/j.imlet.2017.12.001_bib0140","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/j.1445-5994.2005.00783.x","article-title":"Systemic scleroderma: a spatiotemporal clustering","volume":"35","author":"Englert","year":"2005","journal-title":"Intern. Med. J."},{"key":"10.1016\/j.imlet.2017.12.001_bib0145","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00281-015-0507-3","article-title":"Environmental risk factors of systemic sclerosis","volume":"37","author":"Marie","year":"2015","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.imlet.2017.12.001_bib0150","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1002\/1529-0131(200106)44:6<1359::AID-ART228>3.0.CO;2-S","article-title":"Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts","volume":"44","author":"Arnett","year":"2001","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.imlet.2017.12.001_bib0155","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1002\/art.11173","article-title":"Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies","volume":"48","author":"Feghali-Bostwick","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.imlet.2017.12.001_bib0160","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.jcv.2014.10.003","article-title":"Acute and regressive scleroderma concomitant to an acute CMV primary infection","volume":"61","author":"Goulabchand","year":"2014","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.imlet.2017.12.001_bib0165","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/j.1749-6632.2009.04808.x","article-title":"The role of infections in the immunopathogensis of systemic sclerosis\u2013evidence from serological studies","volume":"1173","author":"Arnson","year":"2009","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.imlet.2017.12.001_bib0170","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1093\/rheumatology\/ken370","article-title":"Proteomic analysis of scleroderma lesional skin reveals activated wound healing phenotype of epidermal cell layer","volume":"47","author":"Aden","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.imlet.2017.12.001_bib0175","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1038\/jid.2010.120","article-title":"Epithelial cells promote fibroblast activation via IL-1alpha in systemic sclerosis","volume":"130","author":"Aden","year":"2010","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.imlet.2017.12.001_bib0180","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3109\/08916939908994064","article-title":"Autoimmunity and vascular involvement in systemic sclerosis (SSc)","volume":"31","author":"Kahaleh","year":"1999","journal-title":"Autoimmunity"},{"key":"10.1016\/j.imlet.2017.12.001_bib0185","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1346-8138.1976.tb01832.x","article-title":"Ultrastructure of the microvasculature in skin affected by systemic scleroderma","volume":"3","author":"Saito","year":"1976","journal-title":"J. Dermatol."},{"key":"10.1016\/j.imlet.2017.12.001_bib0190","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2133.1992.tb00100.x","article-title":"Studies of the microvascular endothelium in uninvolved skin of patients with systemic sclerosis: direct evidence for a generalized microangiopathy","volume":"126","author":"Freemont","year":"1992","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.imlet.2017.12.001_bib0195","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1056\/NEJMra0806188","article-title":"Scleroderma","volume":"360","author":"Gabrielli","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.imlet.2017.12.001_bib0200","doi-asserted-by":"crossref","first-page":"ra84","DOI":"10.1126\/scisignal.2004592","article-title":"Oxidative DNA damage induces the ATM-mediated transcriptional suppression of the Wnt inhibitor WIF-1 in systemic sclerosis and fibrosis","volume":"7","author":"Svegliati","year":"2014","journal-title":"Sci. Signal."},{"key":"10.1016\/j.imlet.2017.12.001_bib0205","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0140-6736(04)16853-0","article-title":"Defective vasculogenesis in systemic sclerosis","volume":"364","author":"Kuwana","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.imlet.2017.12.001_bib0210","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1093\/rheumatology\/34.11.1048","article-title":"Serial circulating adhesion molecule levels reflect disease severity in systemic sclerosis","volume":"34","author":"Denton","year":"1995","journal-title":"Br. J. Rheumatol."},{"key":"10.1016\/j.imlet.2017.12.001_bib0215","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1136\/annrheumdis-2012-201958","article-title":"Toll-like receptor-mediated, enhanced production of profibrotic TIMP-1 in monocytes from patients with systemic sclerosis: role of serum factors","volume":"72","author":"Ciechomska","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.imlet.2017.12.001_bib0220","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/0014-5793(89)80590-3","article-title":"Human monocyte chemoattractant protein-1 (MCP-1). Full-length cDNA cloning, expression in mitogen-stimulated blood mononuclear leukocytes, and sequence similarity to mouse competence gene JE","volume":"244","author":"Yoshimura","year":"1989","journal-title":"FEBS Lett."},{"key":"10.1016\/j.imlet.2017.12.001_bib0225","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1046\/j.1365-2249.1998.00721.x","article-title":"Scleroderma fibroblasts promote migration of mononuclear leucocytes across endothelial cell monolayers","volume":"114","author":"Denton","year":"1998","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.imlet.2017.12.001_bib0230","first-page":"275","article-title":"Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis","volume":"33","author":"Matsushita","year":"2006","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.imlet.2017.12.001_bib0235","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s10067-010-1610-4","article-title":"Serum chemokine and cytokine levels as indicators of disease activity in patients with systemic sclerosis","volume":"30","author":"Hasegawa","year":"2011","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.imlet.2017.12.001_bib0240","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1002\/art.21396","article-title":"Chemokine receptor CCR2 expression by systemic sclerosis fibroblasts: evidence for autocrine regulation of myofibroblast differentiation","volume":"52","author":"Carulli","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.imlet.2017.12.001_bib0245","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1136\/ard.2006.067967","article-title":"Can CCL2 serum levels be used in risk stratification or to monitor treatment response in systemic sclerosis?","volume":"67","author":"Carulli","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.imlet.2017.12.001_bib0250","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/jlb.62.5.681","article-title":"MIP-1alpha and MCP-1 differentially regulate acute and relapsing autoimmune encephalomyelitis as well as Th1\/Th2 lymphocyte differentiation","volume":"62","author":"Karpus","year":"1997","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.imlet.2017.12.001_bib0255","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1002\/art.11164","article-title":"Monocyte chemoattractant protein 3 as a mediator of fibrosis: overexpression in systemic sclerosis and the type 1 tight-skin mouse","volume":"48","author":"Ong","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.imlet.2017.12.001_bib0260","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1136\/ard.2005.040782","article-title":"Serum levels of monocyte chemotactic protein-3\/CCL7 are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis","volume":"65","author":"Yanaba","year":"2006","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.imlet.2017.12.001_bib0265","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1093\/rheumatology\/ken401","article-title":"Monocyte chemoattractant proteins in the pathogenesis of systemic sclerosis","volume":"48","author":"Distler","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.imlet.2017.12.001_bib0270","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/ard.2003.018705","article-title":"Up regulated expression of fractalkine\/CX3CL1 and CX3CR1 in patients with systemic sclerosis","volume":"64","author":"Hasegawa","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.imlet.2017.12.001_bib0275","doi-asserted-by":"crossref","first-page":"R18","DOI":"10.1186\/ar3242","article-title":"Dysregulated expression of MIG\/CXCL9, IP-10\/CXCL10 and CXCL16 and their receptors in systemic sclerosis","volume":"13","author":"Rabquer","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.imlet.2017.12.001_bib0280","first-page":"S44","article-title":"CCL2, CCL3 and CCL5 chemokines in systemic sclerosis: the correlation with SSc clinical features and the effect of prostaglandin E1 treatment","volume":"30","author":"Bandinelli","year":"2012","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.imlet.2017.12.001_bib0285","first-page":"e436","article-title":"The Th1 chemokine IP-10 in systemic sclerosis","volume":"165","author":"Corrado","year":"2014","journal-title":"Clin. Ther."},{"key":"10.1016\/j.imlet.2017.12.001_bib0290","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.4049\/jimmunol.141.3.1018","article-title":"A human T cell-specific molecule is a member of a new gene family","volume":"141","author":"Schall","year":"1988","journal-title":"J. Immunol."},{"key":"10.1016\/j.imlet.2017.12.001_bib0295","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1084\/jem.168.6.2251","article-title":"Resolution of the two components of macrophage inflammatory protein 1, and cloning and characterization of one of those components, macrophage inflammatory protein 1 beta","volume":"168","author":"Sherry","year":"1988","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.imlet.2017.12.001_bib0300","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1126\/science.7682337","article-title":"Preferential migration of activated CD4+ and CD8+ T cells in response to MIP-1 alpha and MIP-1 beta","volume":"260","author":"Taub","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.imlet.2017.12.001_bib0305","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.3109\/s10165-012-0795-6","article-title":"Serum chemokine levels as prognostic markers in patients with early systemic sclerosis: a multicenter, prospective, observational study","volume":"23","author":"Hasegawa","year":"2013","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.imlet.2017.12.001_bib0310","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.4049\/jimmunol.168.6.3088","article-title":"Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: cutaneous cytokines, chemokines, and immune cell activation","volume":"168","author":"Zhang","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.imlet.2017.12.001_bib0315","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/art.1780400422","article-title":"Cytokine concentrations in bronchoalveolar lavage fluid of patients with systemic sclerosis","volume":"40","author":"Bolster","year":"1997","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.imlet.2017.12.001_bib0320","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s004030000134","article-title":"Chemokine release from activated human dermal microvascular endothelial cells\u2013implications for the pathophysiology of scleroderma?","volume":"292","author":"Anderegg","year":"2000","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.imlet.2017.12.001_bib0325","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1002\/art.24049","article-title":"Antifibroblast antibodies in systemic sclerosis induce fibroblasts to produce profibrotic chemokines, with partial exploitation of toll-like receptor 4","volume":"58","author":"Fineschi","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.imlet.2017.12.001_bib0330","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/eci.12776","article-title":"The role of microRNA-5196 in the pathogenesis of systemic sclerosis","volume":"47","author":"Ciechomska","year":"2017","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.imlet.2017.12.001_bib0335","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/385640a0","article-title":"A new class of membrane-bound chemokine with a CX3C motif","volume":"385","author":"Bazan","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.imlet.2017.12.001_bib0340","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1111\/j.1582-4934.2009.00787.x","article-title":"CX3CL1\/fractalkine shedding by human hepatic stellate cells: contribution to chronic inflammation in the liver","volume":"13","author":"Bourd-Boittin","year":"2009","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.imlet.2017.12.001_bib0345","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0092-8674(00)80438-9","article-title":"Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion","volume":"91","author":"Imai","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.imlet.2017.12.001_bib0350","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/17402520500303297","article-title":"Polymorphism of the fractalkine receptor CX3CR1 and systemic sclerosis-associated pulmonary arterial hypertension","volume":"12","author":"Marasini","year":"2005","journal-title":"Clin. Dev. Immunol."},{"key":"10.1016\/j.imlet.2017.12.001_bib0355","first-page":"527","article-title":"Increased serum fractalkine in systemic sclerosis: down-regulation by prostaglandin E1","volume":"26","author":"Sicinska","year":"2008","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.imlet.2017.12.001_bib0360","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13075-015-0575-8","article-title":"Multiplex cytokine analysis of dermal interstitial blister fluid defines local disease mechanisms in systemic sclerosis","volume":"17","author":"Clark","year":"2015","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.imlet.2017.12.001_bib0365","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/eji.1830250113","article-title":"Actions of the chemotactic cytokines MCP-1, MCP-2, MCP-3, RANTES, MIP-1 alpha and MIP-1 beta on human monocytes","volume":"25","author":"Uguccioni","year":"1995","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.imlet.2017.12.001_bib0370","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1136\/ard.2010.137349","article-title":"An investigation of the inflammatory cytokine and chemokine network in systemic sclerosis","volume":"70","author":"Codullo","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.imlet.2017.12.001_bib0375","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.2353\/ajpath.2008.070832","article-title":"A novel mechanism for CCR4 in the regulation of macrophage activation in bleomycin-induced pulmonary fibrosis","volume":"172","author":"Trujillo","year":"2008","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.imlet.2017.12.001_bib0380","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","article-title":"Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial","volume":"387","author":"Khanna","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.imlet.2017.12.001_bib0385","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1172\/JCI77958","article-title":"Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients","volume":"125","author":"Rice","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.imlet.2017.12.001_bib0390","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1084\/jem.186.1.131","article-title":"An antagonist of monocyte chemoattractant protein 1 (MCP-1) inhibits arthritis in the MRL-lpr mouse model","volume":"186","author":"Gong","year":"1997","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.imlet.2017.12.001_bib0395","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.bcp.2011.12.001","article-title":"A truncated analogue of CCL2 mediates anti-fibrotic effects on murine fibroblasts independently of CCR2","volume":"83","author":"Kalderen","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.imlet.2017.12.001_bib0400","doi-asserted-by":"crossref","first-page":"e0184694","DOI":"10.1371\/journal.pone.0184694","article-title":"Differential impact of the dual CCR2\/CCR5 inhibitor cenicriviroc on migration of monocyte and lymphocyte subsets in acute liver injury","volume":"12","author":"Puengel","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.imlet.2017.12.001_bib0405","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1002\/art.21975","article-title":"A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis","volume":"54","author":"Haringman","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.imlet.2017.12.001_bib0410","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S2213-8587(15)00261-2","article-title":"The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial","volume":"3","author":"de Zeeuw","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.imlet.2017.12.001_bib0415","doi-asserted-by":"crossref","first-page":"F1288","DOI":"10.1152\/ajprenal.00316.2013","article-title":"CCR2 antagonist CCX140-B provides renal and glycemic benefits in diabetic transgenic human CCR2 knockin mice","volume":"305","author":"Sullivan","year":"2013","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.imlet.2017.12.001_bib0420","doi-asserted-by":"crossref","first-page":"e60094","DOI":"10.1371\/journal.pone.0060094","article-title":"A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn\u2019s disease","volume":"8","author":"Keshav","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.imlet.2017.12.001_bib0425","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1136\/annrheumdis-2011-201605","article-title":"Chemokine receptor CCR1 antagonist CCX354-C treatment for rheumatoid arthritis: CARAT-2, a randomised, placebo controlled clinical trial","volume":"72","author":"Tak","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.imlet.2017.12.001_bib0430","doi-asserted-by":"crossref","first-page":"29562","DOI":"10.1074\/jbc.M113.498436","article-title":"Llama-derived single variable domains (nanobodies) directed against chemokine receptor CXCR7 reduce head and neck cancer cell growth in vivo","volume":"288","author":"Maussang","year":"2013","journal-title":"J. Biol. Chem."}],"container-title":["Immunology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247817304157?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247817304157?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T21:52:37Z","timestamp":1693345957000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165247817304157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":86,"alternative-id":["S0165247817304157"],"URL":"https:\/\/doi.org\/10.1016\/j.imlet.2017.12.001","relation":{},"ISSN":["0165-2478"],"issn-type":[{"value":"0165-2478","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemokines in systemic sclerosis","name":"articletitle","label":"Article Title"},{"value":"Immunology Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.imlet.2017.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}